PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	DIVISIONAL APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-010	09/553,496	
	APPLICANT Sudhir V. Shah		
November 14, 2003	FILING DATE	CONFIRMATION NO.	GROUP 1654
(Use several sheets if necessary)			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
W	AA	5,047,421	Sep 10, 1991	Green
W	AB	5,721,209	Feb 24, 1998	Horwitz *et al.*
W	AC	5,811,127	Sep 22, 1998	Milstein *et al.*
W	AD	4,684,482	Aug 4, 1987	Green
	AE			
	AF			
	AG			
	AH			
	AI			
	AJ			
	AK			
	AA2			
	AB2			
	AC2			
	AD2			
	AE2			
	AF2			
	AG2			
	AH2			
	AI2			
	AJ2			
	AK2			
	AA3			
	AB3			
	AC3			

EXAMINER	DATE CONSIDERED
Kaleelen	04/26/04

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	DIVISIONAL APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-010	09/553,496	
	APPLICANT: Sudhir V. Shah		
November 14, 2003	FILING DATE	CONFIRMATION NO.	GROUP: 1654
(Use several sheets if necessary)			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
N	AL	WO 94/01770 A	20 Jan 94	PCT	X	
N	AM	DE 40 08 323 A	19 Sept 91	Germany	X	
N	AN	WO 00 13706 A	16 Mar 00	PCT (English)		
N	AO	WO 91 07956 A	13 June 91	PCT		
	AP					
	AQ					
	AL2					
	AM2					
	AN2					
	AO2					
	AP2					
	AQ2					
	AL3					
	AM3					
	AN3					
	AO3					
	AP3					
	AQ3					
	AL4					
	AM4					
	AN4					
	AO4					
	AP4					
	AQ4					
	AL5					
	AM5					

EXAMINER	DATE CONSIDERED
[signature]	04/26/04

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	DIVISIONAL APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-010	09/553,496	
November 14, 2003	APPLICANT Sudhir V. Shah		
(Use several sheets if necessary)	FILING DATE	CONFIRMATION NO.	GROUP 1654

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
	AR	Sumboonnanonda, A., *et al.*, "Renal tubular function in β-thalassemia", *Pediatr Nephrol*, 12:280-283.
	AS	Ong-ajyooth, L., *et al.*, "Renal Function in Adult Beta-Thalassemia/Hb E Disease", *Nephron*, 78:156-161 (1998).
	AT	Guasch, A., *et al.*, "Evidence that Microdeletions in the α Globin Gene Protect Against the Development of Sickle Cell Glomerulopathy in Humans", *J Am Soc Nephrol*, 10:1014-1019 (1999).
	AU	Loebstein, R., *et al.*, "Diabetic Nephropathy in Hypertransfused Patients with β-Thalassemia", *Diabetes Care*, 21(8):1306-1309 (1998).
	AV	Ongajyooth, L., *et al.*, "Glomerulonephritis in β-thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome", *J Med Assoc Thai*, 78(3):119-126 (1995).
	AW	Aoki, R.Y., *et al.*, "Microalbuminuria in Sickle Cell Disease", *Brazilian J Med Biol Res*, 23:1103-1106 (1990).
	AX	Katopodis, K.P., *et al.*, "Renal Abnormalities in Patients with Sickle Cell-Beta Thalassemia", *Journal of Nephrology*, 10(3):163-167 (1997).
	AY	Pham, P.-T.T., *et al.*, "Renal abnormalities in sickle cell disease", *Kidney International*, 57:1-8 (2000).
	AZ	Kontoghiorghes, G.J., *et al.*, "Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones", *Inorganica Chimica Acta.*, 136:L11-L12 (1987).
	AR2	Falk, R.J., *et al.*, "Prevalence and Pathologic Features of Sickle Cell Nephropathy and Response to Inhibition of Angiotensin-Convertng Enzyme", *The New England Journal of Medicine*, 326(14):910-915 (1992).
	AS2	Guasch, A., *et al.*, "Sickle cell anemia causes a distinct pattern of glomerular dysfunction", *Kidney International*, 51:826-833 (1997).
	AT2	Cianciulli, P., *et al.*, "Early detection of nephrotoxic effets in thalassemic patients receiving desferrioxamine therapy", *Kidney International*, 46:467-470 (1994).
	AU2	Ueda, N., *et al.*, "Role of 'catalytic' iron in an animal model of minimal change nephrotic syndrome", *Kidney International*, 49:370-373 (1996).

EXAMINER	DATE CONSIDERED
	04/26/04

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	DIVISIONAL APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-010	09/553,496	
	APPLICANT Sudhir V. Shah		
November 14, 2003	FILING DATE	CONFIRMATION NO.	GROUP 1654
(Use several sheets if necessary)			

		OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*
	AV2	Savill, J., *et al.*, "Mechanisms of glomerular injury". In "Oxford Textbook of Clinical Nephrology," 2nd ed., pages 404-439, eds., Davidson, A.M., *et al.*, Oxford Univ. Press (1998).
	AW2	Ueda, N., *et al.*, "*In Vivo* Evidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease", *Kidney: A Current Survey of World Literature*, 6:143-146 (1997).
	AX2	Boyce, N.W., *et al.*, "Hydroxyl radical mediation of immune renal injury by desferrioxamine", *Kidney International*, 30:813-817 (1986).
	AY2	Baliga, R., *et al.*, "Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet", *J Am Soc Nephrol*, 7(8):1183-1188 (1996).
	AZ2	Shah, S.V., "Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats", *The American Physiological Society*, F337-F344(1988).
	AR3	Thakur, V., *et al.*, "Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria", *Kidney International*, 34:494-499 (1988).
	AS3	Nankivell, B.J., *et al.*, "The Role of Tubular Iron Accumulation in the Remnant Kidney", *J Am Soc Nephrol*, 4(8):1598-1607 (1994).
	AT3	Alfrey, A.C., *et al.*, "Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis", *Kidney International*, 36:753-759 (1989).
	AU3	El Nahas, A.M., "Mechanisms of experimental and clinical renal scarring" In: "Oxford Textbook of Clinical Nephrology", 2nd ed., pages 1749-1788, eds., Davidson, A.M., *et al.*, Oxford Univ. Press (1998).
	AV3	Howard R.L., *et al.*, "Urinary albumin, transferrin and iron excretion in diabetic patients", *International Society of Nephrology*, 40:923-926 (1991).
	AW3	Olivieri, N.F., *et al.*, "Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major", *The New England Journal of Medicine*, 918-922 (1995).
	AX3	Alfrey A.C., "Toxicity of tubule fluid iron in the nephrotic syndrome", *American Journal of Physiology*, 263(4):F637-F641 (1992).
	AY3	Wu,Z-L, *et al.*, "Iron Loading Enhances Susceptibility to Renal Ischemia in Rats," *Renal Failure* 16(4):471-480 (1994).

EXAMINER	DATE CONSIDERED
	04/26/04

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	DIVISIONAL APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	2629.1003-010	09/553,496	
November 14, 2003	APPLICANT Sudhir V. Shah		
(Use several sheets if necessary)	FILING DATE	CONFIRMATION NO.	GROUP 1654

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*		
✓	AZ3	Baliga, R. *et al.*, "In Vitro and In Vivo Evidence Suggesting a Role for Iron in Cistaplin-induced Nephrotoxicity," *Kidney International* 53(2):394-401 (February 1998).
✓	AR4	Harris, D. *et al.*, "Mitrochondrial Function in Rat Renal Cortex in Response to Proteinuria and Iron," *Clinical and Experimental Pharmacology and Physiology* 24:916-922 (December 1997).

EXAMINER	DATE CONSIDERED
	04/26/04